Floatz logo

Adezunap

Diabetic Polyneuropathy

Apurano Pharmaceuticals GmbHPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Diabetic Polyneuropathy cohort.

Asset / SponsorPhaseRating
Duloxetine
University of Rochester
Phase 4BB
Pregabalin
Syeda Khatoon e Jannat Welfare Foundation
Phase 4BB
(±)-TRAMADOL
Turku University Hospital
Phase 4BB
Capsaicin
Thammasat University
Phase 2/3B
Oxycodone
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3B

View all 20 →

Same molecule, other indications

Adezunap is also rated in:

Post Operative PainDormant
B
Indicative ·
60 / 100
View asset →
Pain SyndromeDormant
B
Indicative ·
60 / 100
View asset →
Central Neuropathic PainDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →